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Key points;  
 
1. Stimulation of the B-cell receptor of chronic lymphocytic leukemia cells results 
in activation of an unfolded protein response. 
 
2. Unfolded protein response activation following surface immunoglobulin M 






B-cell receptor (BCR) signaling plays a key role in the behavior of chronic 
lymphocytic leukemia (CLL). However, cellular consequences of signaling are 
incompletely defined. Here we explored possible links between BCR signaling 
and the unfolded protein response (UPR), a stress response pathway which can 
promote survival of normal and malignant cells. Compared to normal B cells, 
circulating CLL cells expressed increased, but variable, levels of UPR 
components. Higher expression of CHOP and XBP1 RNAs were associated with 
more aggressive disease. UPR activation appeared due to prior tissue-based 
antigenic stimulation since elevated expression of UPR components was 
detected within lymph node proliferation centers. Basal UPR activation also 
correlated closely with surface IgM (sIgM) signaling capacity in vitro in both IGHV 
unmutated (U)CLL and within mutated (M)CLL. sIgM signaling increased UPR 
activation in vitro with responders showing increased expression of CHOP and 
XBP1 RNAs, and PERK and BIP proteins, but not XBP1 splicing. Inhibitors of 
BCR-associated kinases effectively prevented sIgM-induced UPR activation. 
Overall, the study demonstrates that sIgM signaling results in activation of some 
components the UPR in CLL cells. Modulation of the UPR may contribute to 
variable clinical behavior, and its inhibition may contribute to clinical responses to 
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Chronic lymphocytic leukemia (CLL) provides a unique opportunity to understand 
how antigen can influence the behavior of malignant lymphocytes.  It also acts as 
a model for the development of novel therapies targeted towards B-cell receptor 
(BCR) signaling pathways.1-4 CLL comprises two major subsets with differing 
levels of somatic hypermutation of tumor IGV genes. CLL with unmutated IGV 
(U-CLL) derives from naïve CD5+CD27- B cells of the normal natural antibody 
repertoire, whereas CLL with mutated IGV genes (M-CLL) may derive from post-
germinal center CD5+CD27+ cells.5,6 Importantly, these subsets have distinct 
clinical behavior and U-CLL has a more aggressive clinical course. Antigen 
signaling is thought to be on-going in both subsets and, rather than the presence 
or absence of signaling, it is the balance between distinct types of responses that 
appears to determine clinical behavior.1 Anergy, a state of cellular lethargy that is 
induced following antigen engagement in the absence of T-cell help,7 is observed 
in all CLL but is particularly prominent in M-CLL.1 By contrast, positive antigen 
signaling leading to proliferation and survival appears more evident in U-CLL. 
The importance of antigen signaling for CLL is emphasized by recent results 
which have demonstrated the clinical effectiveness of inhibitors of BCR-
associated kinases.8 
 
Antigen engagement in vivo is thought to occur within proliferation centers (PC) 
found predominantly in the lymph nodes (LN) of CLL patients. Following 
stimulation, CLL cells enter the circulation and therefore carry a temporary 
“imprint” of their prior tissue based stimulation.9,10 Thus, markers of anergy,7 
including strong down-modulation of surface IgM (sIgM) expression and signaling 
capacity, raised ERK1/2 phosphorylation and NFAT expression, can be detected 
in blood CLL cells, most prominently in M-CLL.11-13 In contrast to M-CLL, blood 
cells from patients with U-CLL tend to retain sIgM expression and signaling 
responsiveness, and express higher levels of markers of “positive” BCR 
signaling, including the proliferation and survival-promoting proteins, MYC and 
MCL1.14,15 Positive signaling can be mimicked in vitro by treating CLL cells with 
anti-IgM antibodies which increases expression of these markers in samples that 
retain sIgM responsiveness.16,17 Although the overall behavior of U-CLL and M-
CLL is distinct, there is heterogeneity within these subsets, especially within M-
CLL.11 For example, high levels of sIgM expression and signaling in M-CLL may 
highlight a subset at higher risk of progression. Indeed, our previous study 
demonstrated that anti-IgM-induced BIM phosphorylation was associated with 
requirement for treatment, including within the M-CLL subset.18 
 
Despite recent advances, the consequences of BCR stimulation in CLL remain 
incompletely understood. In this work we have investigated the effects of sIgM 
stimulation on the unfolded protein response (UPR). The UPR has been most 
widely studied as a stress response pathway which responds to accumulation of 
unfolded/mis-folded proteins and/or elevated secretory protein synthesis within 
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the endoplasmic reticulum (ER) lumen.19,20  See Supplementary Figure 1 for a 
summary of UPR molecules and pathways.  
 
In B cells, the UPR plays key roles in differentiation since production of secreted 
immunoglobulin (Ig) by plasma cells requires a compensatory increase in protein 
production capacity mediated by UPR induction.21 Thus, XBP1 and IRE1 are 
essential for plasma cell development.22-24 The UPR is also essential for the 
survival of multiple myeloma cells and is an established therapeutic target in this 
disease.25-27 However, the UPR plays other roles in B cells, independent of its 
requirement to support increased secretory Ig synthesis per se, including for 
differentiation beyond the pro-B-cell stage.24 In mature B cells, differentiation-
promoting factors, such as IL4 or LPS, rapidly activate a subset of UPR 
components prior to increased Ig synthesis and the UPR is activated normally in 
cells that lack the ability to secrete IgM.23,28-30 BCR stimulation has also been 
shown to increase some UPR components although this stimulation alone is not 
sufficient to promote differentiation.31 Thus, UPR activation is not simply a 
consequence of stress, but can be a signal-regulated pathway that induces a 
partial, “anticipatory” response which prepares B cells for subsequent antibody 
production. In contrast to these physiological pro-survival responses, prolonged, 
high-level UPR activation in response to pharmacological agents (such as 
proteasome inhibitors which cause accumulation of mis-folded proteins) induces 
a cell death-promoting UPR response.19,20 
 
Previous studies have shown that CLL cells express some UPR components and 
that pharmacological inducers of the UPR promote apoptosis of CLL cells in 
vitro.32-36 However, the potential regulation of the UPR following BCR stimulation 
of CLL cells has not been studied. In this paper, we demonstrate for the first time 
that sIgM stimulation results in a “partial” activation of the UPR, with selective 
activation of specific downstream UPR effector pathways. Higher levels of UPR 
activation correlated with more aggressive disease and BCR-targeted kinase 
inhibitors decreased UPR activation suggesting that this reponse may contribute 
to disease progression and that its inhibition may be important for clinical activity 




Materials and methods 
 
Patients and cell samples 
 
Patients were recruited after written informed consent was provided in 
accordance with Ethics Committee approvals and the Declaration of Helsinki. 
Blood was obtained from patients with IgM+IgD+ CLL with a diagnostic phenotype 
who attended Hematology outpatient clinics at the Leicester Royal Infirmary, 
Portsmouth Hospital, Southampton General Hospital, the Royal Wolverhampton 
Hospitals NHS Trust or the Royal Berkshire Hospital, Reading (all UK). Clinical 
 5 
details for the patients studied are given in Supplementary Table 1. The 
majority of samples were obtained at or shortly after diagnosis and mainly prior to 
any therapy for CLL. Where treatment for CLL had taken place, this was at least 
6 months prior to sample collection. Disease was considered to be more 
aggressive if there were signs of clinical progression and/or the patient was 
treated for CLL at any point following diagnosis. 
 
Blood samples were processed as previously described.11 Cell viability 
determined by trypan blue exclusion was ≥90%. The proportion of CD5+CD19+ 
CLL cells was >80% in all cases. IGHV mutation status, expression of cell 
surface CD5, CD19 and CD38, and ZAP70 were determined as previously 
described.11,37 IgM signaling capacity was determined by measuring the 
percentage of cells with increased intracellular calcium following stimulation with 
soluble goat F(ab’)2 anti-IgM and using a cut-off value of 5% responding cells to 
define samples as sIgM responsive.11 Normal B cells were isolated from 
peripheral blood or buffy coats from healthy donors using the B cell Isolation Kit II 
with the addition of anti-CD138 Microbeads (both Miltenyi Biotec, Bisley, UK) to 
ensure effective depletion of plasma cells.  
 
 






“Basal” activation of UPR-associated pathways in CLL and normal B cells 
 
We first analyzed “basal” activation of the UPR (ie, in unstimulated cells) in CLL 
samples isolated from the blood of 40 patients using Q-PCR to quantify 
expression of XBP1 and CHOP RNAs. The samples comprised 20 U-CLL which, 
as previously described,11 generally retained sIgM signaling responsiveness. We 
also analyzed 20 M-CLL samples.These samples were selected to contain a 
substantial proportion of sIgM signal-competent samples to allow us to probe 
potential correlations between UPR activation and sIgM signaling within this 
subset. Circulating B cells from healthy individuals were analyzed as controls. To 
validate the Q-PCR assays, CLL samples were treated with the pharmacological 
UPR inducer thapsigargin. As expected, thapsigargin substantially increased 
XBP1 and CHOP RNA expression in CLL samples (Supplementary Figure 2A).    
 
Although basal expression of CHOP and XBP1 RNAs were variable between 
individual CLL samples, median CHOP and XBP1 RNA expression levels were 
significantly higher than normal B cells (Figure 1A). CHOP and XBP1 RNA 
expression levels were closely correlated demonstrating that these RNAs are 
generally co-expressed in individual CLL samples (Figure 1B).  
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We extended these results by examining other features of UPR activation in 
unstimulated CLL cells including BIP, PERK and the PERK substrate eIF2. We 
were unable to identify antibodies suitable for reliable analysis of XBP1 and 
CHOP protein expression in CLL cells. As expected, thapsigargin increased BIP 
protein expression, and phosphorylation of PERK (detected by reduced 
migration) and eIF2 (detected using a phospho-specific antibody) 
(Supplementary Figure 2B). Immunoblotting demonstrated that basal 
expression of BIP protein was elevated in some CLL samples compared to 
normal B cells (Figure 1C). We also detected moderately increased PERK 
expression in some CLL samples compared to normal B cells but not a clear 
decrease in PERK mobility as observed in thapsigargin-treated CLL cells. 
Consistent with weak PERK activation in CLL cells, we detected only very 
modest levels eIF2 phosphorylation in some samples.    
 
Although we detected raised XBP1 RNA in unstimulated CLL samples, there was 
little evidence for accumulation of XBP1S; very low levels of basal expression of 
XBP1S RNA were detected in only 2/18 untreated CLL cell samples (not shown). 
XBP1S expression was detected in thapsigargin-treated cells confirming the 
validity of the assay. However, even in thapsigargin-treated cells, XBP1S RNA 
levels were relatively low level (Supplementary Figure 3).    
 
Overall, these results demonstrate substantial but variable basal activation of 
some UPR components in CLL blood cells.  
 
 
Correlations between basal UPR activation and sIgM signaling capacity in vitro 
 
We next investigated potential correlations between basal UPR activation and 
sIgM signaling capacity measured using anti-IgM-induced intracellular Ca2+ 
mobilization. When considering the total cohort, there were significant 
correlations between sIgM signaling capacity in vitro and CHOP and XBP1 RNA 
expression levels with higher basal level expression of these RNAs associated 
with retained sIgM signaling capacity (Figure 2A,B). Similar to the complete 
cohort, there was a positive correlation between signaling capacity and CHOP 
RNA levels when U-CLL and M-CLL samples were considered separately 
(Figure 2C,E). There was a similar trend for XBP1 RNA but this did not reach 
statistical significance (Figure 2D,F). Thus, basal UPR activation correlates with 
sIgM signaling capacity in vitro, in both the M-CLL and U-CLL subsets. 
Consistent with the correlation between UPR activation and retained signal 
capacity, there were trends towards increased CHOP/XBP1 RNA expression in 
U-CLL (Supplementary Figure 4). However, it is important to emphasize, that 
these differences did not reach statistical significance, most likely due to the 
enrichment for M-CLL signal competent samples in the current cohort. 
 
 
Correlation between basal UPR activation and clinical behavior 
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To begin to probe the potential clinical significance of UPR activation, we also 
investigated whether variable basal UPR activation correlated with clinical 
behavior depending on whether the patient had indolent or more aggressive 
disease (see Materials and methods). Higher basal CHOP or XBP1 RNA levels 
were associated with more aggressive disease in the total cohort (Figure 3A,B). 
Similar correlations were detected when only Binet stage A disease (U-CLL and 
M-CLL combined) was analyzed (n=23) (Figure 3C,D). There was also 
consistently higher expression of CHOP or XBP1 RNAs in more aggressive 
disease compared to indolent disease specifically within the M-CLL subset (all 
stages) although this was only significant for XBP1 (Figure 3E,F). There were 
only two cases of indolent disease amongst the 17 U-CLL samples analyzed 
where outcome data was available precluding meaningful analysis of this subset. 
These observations provide further support for the idea that high basal UPR 
activation is associated with retained sIgM signaling and that these features may 
be associated with relatively aggressive disease, possibly even within M-CLL. 
 
 
Effect of sIgM engagement on UPR activation 
 
The correlation between basal UPR activation and retained sIgM signaling 
capacity suggested that UPR activation was directly linked to the capacity to 
respond to antigen stimulation in vivo. Activation of sIgM in vitro using anti-IgM 
antibodies mimics positive BCR signaling in CLL. Therefore, to determine directly 
whether sIgM stimulation activated the UPR in CLL cells, we investigated the 
effects of anti-IgM on XBP1/CHOP RNA expression. Normal B cells were 
analyzed as controls. 
 
In normal B cells, soluble anti-IgM increased expression of CHOP RNA most 
strongly at 1 hour and less so at 6 hours post-stimulation (Figure 4A). Induction 
of XBP1 RNA was greatest at 6 hours post-stimulation. Similar experiments were 
performed using CLL samples all of which were classed as sIgM signal 
responsive. There were significant increases in CHOP and XBP1 RNA 
expression following treatment with soluble anti-IgM compared to control cells 
(Figure 4B). However, similar to other sIgM signaling responses,38 increases in 
CHOP/XBP1 RNAs were much weaker than in normal B cells. 
 
The weak induction of CHOP/XBP1 RNAs in CLL samples may reflect the low 
level of sIgM expression in these cells, a consequence of anergy-promoting 
interactions in vivo.7,11 Since BCR signal strength in CLL cells can be enhanced 
by treating cells with immobilized anti-IgM16 we also stimulated sIgM signal 
responsive CLL samples with anti-IgM bound to Dynabeads (Figure 4B). Cells 
were analyzed at 6 hours post-stimulation since the onset of signaling is delayed 
in cells treated with bead-bound9 compared to soluble antibodies,17 presumably 
due to potentially slower engagement of sIgM. Compared to soluble antibodies, 
bead-bound anti-IgM triggered larger increases in CHOP/XBP1 RNA expression 
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(Figure 4B). Considering all data for anti-IgM treated cells, there was a strong 
positive correlation between induction of XBP1 and CHOP RNAs (Figure 4C). 
Consistent with the stronger signal, increases in phosphorylation of ERK1/2 and 
AKT was greater and longer-lasting in cells treated with bead-bound compared to 
soluble anti-IgM (Supplementary Figure 5). There was considerable variation in 
the extent of anti-IgM-induced CHOP/XBP1 RNA expression (Figure 4B). 
However, the fold increase in CHOP or XBP1 RNA expression did not differ 
between M-CLL and U-CLL in this cohort of signaling competent samples, and 
did not correlate with ZAP-70 expression or sIgM expression (data not shown). 
 
We performed similar experiments to determine whether anti-IgM also induced 
protein markers of the UPR in CLL using 15 signaling responsive samples. 
Treatment with anti-IgM increased expression of both PERK and BIP (Figure 
5A,B). The induction by soluble anti-IgM was significant for some time points, 
however, levels of induction were greater for bead-bound anti-IgM. Similar to 
CHOP/XBP1 RNAs, there was considerable variation in the extent of anti-IgM-
induced PERK/BIP expression (Figure 5A,B) although these parameters 
correlated closely within individual samples indicating co-regulation (Figure 5C). 
As expected, anti-IgM also induced ERK1/2 phosphorylation (Figure 5A). 
Thapsigargin also induced ERK1/2 phosphorylation in a subset of samples. 
 
Variable induction of PERK/BIP was not clearly different between M-CLL and U-
CLL samples and did not correlate with ZAP-70 expression or sIgM expression. 
However, variation in the extent of PERK/BIP induction did appear to be related 
to “strength” of sIgM-induced signaling analyzed using other read-outs. First, 
there was no evidence for induction of PERK or BIP expression in 4 non-
responsive samples (Supplementary Figure 6). Second, there was a modest, 
but significant correlation between anti-IgM-induced ERK1/2 phosphorylation and 
BIP/PERK induction in a subset of signal responsive samples (Supplementary 
Figure 7). sIgM stimulation also increased BIP and PERK expression in normal 
B cells, although analysis was technically difficult due to the small number of B 
cells obtained for immunoblot analysis (Supplementary Figure 8). Similar to 
unstimulated cells, we did not detect increased XBP1S expression in CLL cells 
treated with anti-IgM (data not shown).  
 
 
Expression of UPR associated components in vivo 
 
We performed immunohistochemistry to investigate UPR activation in the LN of 
patients with CLL/small lymphocytic lymphoma (SLL) (Figure 6 and 
Supplementary Table 2). Because of the absence of suitable antibodies, 
analysis was restricted to PERK and XBP1. Comparisons were made to multiple 
myeloma, known to be associated with UPR activation.39 
 
Overall, PERK and XBP1 were widely detected in LNs samples; 11/11 and 
10/11 samples were positive for PERK and XBP1 expression, respectively. 
 9 
Similar to myeloma samples, PERK immunostaining was largely extranuclear, 
consistent with ER-localization. In CLL, PERK was more strongly expressed in 
cells within PCs compared to surrounding cells in 6/11 samples. In 1 additional 
sample,  expression was only detected in malignant cells within PCs. In the other 
samples, PERK expression was not different between cells within and outside of 
PCs. There was also variability in the distribution of XBP1 between individual 
samples, but two broad patterns of expression were observed. In 5/10 positive 
samples, XBP1 was predominantly detected in the nucleus (similar to the 
localization in myeloma samples) in cells outside of PCs. In the other positive 
samples, XBP1 expression was predominantly localized outside of the nucleus 
and in these samples, expression was mainly detected in leukemic blasts within 
PCs. Overall, the analysis demonstrates that UPR-associated proteins were 
expressed within malignant LNs. Although there was substantial intrasample 
variation,  features were frequently more prominent in cells within PCs consistent 
with the idea that UPR activation in CLL cells is a consequence of antigen 
engagement in vivo. Clinical data and/or matched blood samples were not 
available for these samples, so we were unable to correlate this variation to 
outcome or variable sIgM signaling capacity. 
 
To explore further potential regulation of the UPR in vivo, we analyzed 
expression of BIP, CHOP and XBP1 RNAs using GEA data from a study 
comparing CLL cells derived from blood and LN.40 The three RNAs were more 
highly expressed in LN samples compared to blood. Differences were significant 
(paired Student’s t-tests) for BIP and CHOP (P<0.0001 and P=0.0014, 
respectively), but not for XBP1 (P=0.8995).  
 
 
Effect of BCR signaling inhibitors on UPR regulation 
 
To investigate whether UPR induction was a direct consequence of activation of 
signaling pathways, CLL cells were pre-treated with inhibitors of BCR associated 
kinases prior to stimulation with bead-bound anti-IgM. The inhibitors tested were 
the clinical BTK and SYK inhibitors ibrutinib and tamatinib (the active form of 
fostamatinib). Both compounds significantly reduced anti-IgM-induced BIP and 
PERK expression (Figure 7). As expected, both inhibitors also effectively 
blocked induction of phosphorylation of both AKT and ERK1/2 (Figure 7). Thus, 
sIgM-induced UPR activation appears to mediated via kinase-dependent 
signaling pathways and its inhibition may contribute to the therapeutic activity of 






BCR signaling has emerged as a key determinant of the clinical behavior of CLL 
and as an effective target for therapeutic attack. It is important, therefore, to 
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define the functional consequences of sIg stimulation. In this work we 
investigated potential links between the BCR and the UPR, a multifunctional 
response pathway which can promote cell survival or death, dependent on the 
extent and duration of the activating signal. Several studies have shown that 
pharmacological inducers of the UPR promote apoptosis of CLL cells in 
vitro.33,34,36 However, the potential regulation of the UPR following BCR 
stimulation of CLL cells has not been studied previously.  
 
Our results demonstrate that sIgM stimulation results in activation of a partial 
UPR. This conclusion is based on three lines of evidence. First, variable levels of 
basal activation of the UPR in unstimulated, circulating CLL cells correlated 
closely with sIgM signal capacity and were associated with more aggressive 
disease. Second, stimulation of sIgM in vitro increased expression of UPR 
components and this was effectively blocked by BCR-targeted kinase inhibitors, 
including ibrutinib. Third, immunohistochemistry and GEA analysis demonstrated 
relatively high levels of UPR components in LNs in vivo. Interestingly, activation 
and therapeutic targeting of the UPR has also been reported during 
leukemogenesis in the E-TCL1 mouse model of CLL,35,41 although the 
relevance of antigen signaling in vivo in this model remains unclear. 
 
Our analysis demonstrated that sIgM stimulation, especially using bead-bound 
anti-IgM, triggered UPR induction using signal-responsive samples from both the 
M-CLL and U-CLL subsets. By contrast, anti-IgM did not significantly induce UPR 
activation in non-signaling samples indicating that the competency for UPR 
induction broadly correlates with sIgM signaling responsiveness measured using 
canonical read-outs. There was variation in the extent of UPR induction within 
the signal-responsive samples. Although this did not obviously correlate with 
IGHV mutation status, ZAP-70 expression or sIgM expression, there did appear 
to be a correlation between variable BIP/PERK induction and the “strength” of 
sIgM signaling (measured by parallel analysis of ERK1/2 phosphorylation) 
amongst signal-responsive samples. Further studies are required to probe 
relationships between sIgM-induced UPR activation and other signaling 
responses, however, UPR induction is likely to be part of a constellation of 
responses, co-regulated downstream of sIgM in signal-responsive samples.4 
Consistent with this, pre-treatment of samples with ibrutinib or tamatinib 
effectively inhibited anti-IgM-induced UPR activation, providing functional 
evidence for linkage between kinase activation and UPR activation. We did not 
address consequences of sIgD stimulation in this study but have shown 
previously that, although competent for triggering initial calcium responses, anti-
IgD fails to effectively engage downstream responses.17 Consistent with this, a 
recent GEA study showed that BIP RNA was induced in CLL samples following 
stimulation of sIgM, but not sIgD.42 
 
An important finding of the study was that UPR activation in CLL cells was 
partial. There was clear evidence for increased expression of CHOP and XBP1 
RNAs, and BIP protein. However, the PERK arm appeared to be only weakly 
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activated since PERK expression was increased, but without substantial 
phosphorylation, and there were only modest levels of phosphorylation of its 
substrate eIF2. Despite the induction of full length XBP1 RNA, there was little 
evidence for IRE1-dependent processing to XBP1S, consistent with a previous 
study demonstrating only low expression of XBP1S protein in CLL/SLL LN.43 
Treatment of CLL cells with thapsigargin resulted in activation of all arms of the 
UPR. Thus, failure to activate some specific parts of the UPR likely represents 
the consequences of selective regulation rather than inherent defects which 
prevent induction of these specific arms. However, it was noticeable that XBP1S 
splicing was low, even in thapsigargin-treated cells, consistent with the idea that 
activation of this pathway may be relatively weak in CLL.33 
 
Direct analysis of the functional consequences of UPR activation was not 
explored in this work; this would require knockdown of multiple proteins which is 
technically difficult in any cell system, especially in CLL where RNA interference 
(RNAi) is extremely demanding. However, the molecular hallmarks of the partial 
UPR activation in CLL cells is very reminiscent of the “anticipatory” UPR that has 
been described in normal B cells. In this situation, selective activation of some 
UPR components is thought to prepare the cells for subsequent immunoglobulin 
secretion. For example, CHOP and XBP1 RNAs are induced within 1-2 hours 
following treatment of mouse B cells with IL4, whereas XBP1S splicing is 
detected much later at 48 hours post-treatment and is dependent on enhanced Ig 
production.44  
 
As in normal B cells, the partial UPR activation in CLL cells is likely to have a 
pro-survival function. First, anti-IgM-induced UPR activation in CLL cells lacks 
components typically associated with pro-apoptotic responses. IRE1 is the 
principle mediator of UPR-associated apoptosis, via downstream activation of 
pro-apoptotic kinases such as ASK1 and JNK (Supplementary Figure 1). 
However, the absence of substantial XBP1S splicing, which is catalyzed by 
IRE1’s endonuclease activity, indicates that IRE1 is not effectively activated in 
CLL cells. Moreover, anti-IgM stimulation only very weakly induces JNK 
phosphorylation in CLL cells.16 Although CHOP is commonly considered as a 
pro-apoptotic factor, analysis of Chop-deficient mouse B cells has clearly 
demonstrated that CHOP does not play a pro-apoptotic role in B cells.31,45 
Second, UPR activation in CLL cells is associated with increased expression of 
BIP, a chaperone with pro-survival functions.46 For example, in diffuse large B-
cell lymphoma, high level of BIP expression is associated with poor prognosis 
and its overexpression confers resistance to apoptosis in vitro.47 BIP is induced 
in normal murine T cells following stimulation in vitro and its ablation using RNAi 
promotes apoptosis in mouse EL4 T-lymphoma cells.48 The conclusion that 
partial UPR activation in CLL cells promotes survival is consistent with the 
previous observation that RNAi-mediated knock-down of BIP promotes CLL cell 
apoptosis in vitro.32 However, it is possible that UPR activation has additional 
functional consequences. For example, Xbp1 is required for optimal signaling via 
 12 
sIgM and CXCR4, although the functional basis for these effects are 
unknown.28,41 
 
The close correlation between basal UPR activation and retained sIgM signal 
capacity supports the idea that UPR activation is not simply an artifact of 
stimulation in vitro, but can also be a consequence of antigen engagement in 
vivo. Although antigen engagement is thought to be on-going in all CLL, distinct 
biological responses appear to determine clinical behavior.1 Antigen-induced 
anergy is associated with strong down-modulation of sIgM signaling and is most 
prominent in M-CLL.11 By contrast, positive signaling is generally more evident in 
U-CLL and is associated with retained signaling capacity.11 Although the overall 
behavior of U-CLL and M-CLL is distinct, there is heterogeneity within these 
subsets, especially within M-CLL,11 and high levels of retained signaling in M-
CLL may highlight cases at higher risk of progression.18 Overall, UPR activation 
appears to be one of several markers detected in circulating cells that reveal 
prior positive signaling within tissues (Supplementary Figure 9). By contrast, 
strong downmodulation of sIgM signaling responses in vitro (including reduced 
capacity to enhance UPR activation) and lower levels of “basal” UPR activation 
are associated with anergy. Activation of an “anticipatory” UPR is linked to 
differentiation and this linkage between anergy and reduced sIgM-induced UPR 
activation is consistent with the observation that differentiation responses are 
reduced in anergic cells in non-malignant model systems7. Moreover, very recent 
data demonstrate that IL21-induced differentiation responses are suppressed in 
anergic CLL cells.49 Further studies will be required to more accurately define the 
relationship between UPR activation, sIgM signal capacity and disease behavior 
in larger, unselected cohorts. However, the expression of UPR components, 
along with other markers such as MYC and MCL1 which are also induced 
following sIgM-stimulation in vitro may have utility as prognostic or predictive 
markers, including for new BCR-targeted kinase inhibitors, possibly including 
within the M-CLL subset.  
 
In summary, our studies have led to the novel observation that sIgM stimulation 
in CLL cells results in partial activation of the UPR. UPR activation appears to 
contribute to the growth promoting effects of BCR stimulation and is associated 
with more aggressive disease. Inhibition of UPR activation may contribute to the 
therapeutic effects of novel drugs targeted towards BCR-associated signaling 
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Figure 1. Expression of UPR components in unstimulated CLL samples and 
normal B cells 
(A) CHOP and XBP1 RNA expression was quantified by Q-PCR in CLL samples 
(n=40) and normal B cells (n=7). Expression values were normalized so that the 
average value in normal B cells was set to 1.0. Graphs show median and 
individual data points, and the statistical significance of differences between CLL 
samples and normal B cells (Mann-Whitney test). (B) Correlation between CHOP 
and XBP1 RNA expression in CLL samples. The line shows results of linear 
regression and the statistical significance of the correlation is shown (Spearman 
correlation). (C) Immunoblot analysis of BIP, total and phospho-eIF2, PERK 
and GAPDH (loading control) in normal B cells (2 preparations shown) and CLL 
samples. Results shown are representative of more than 30 samples studied 
across a series of separate immunoblots. 
 
Figure 2. Correlations between CHOP and XBP1 RNA expression and sIgM 
signaling capacity  
Correlations between basal CHOP and XBP1 RNA expression and anti-IgM 
signaling responsiveness in (A,B) all samples, (C,D) M-CLL and (E,F) U-CLL. 
The statistical significance of differences was analyzed using the Mann-Whitney 
test. 
 
Figure 3. Correlations between CHOP and XBP1 RNA expression and 
clinical behavior  
Correlations between basal CHOP and XBP1 RNA expression and 
indolent/aggressive disease for (A,B) all CLL/all stages (n=31), (C,D) stage A (M-
CLL and U-CLL combined) (n=23) and (E,F) M-CLL (all stages) (n=19). The 
statistical significance of differences was analyzed using Mann-Whitney test. 
 
Figure 4. Regulation of CHOP and XBP1 RNA expression by anti-IgM 
(A) Normal B cells and (B) CLL samples were stimulated with soluble (sol) or 
bead-bound (bead) anti-IgM for 1 or 6 h and expression of CHOP and XBP1 
RNAs analyzed by Q-PCR. Expression values were normalized so that the 
average value in control normal and CLL cells was set to 1.0. Graphs show mean 
values (±SD) for data obtained with 6 or 4 preparations of normal B cells (for 
CHOP and XBP1 analysis, respectively). For experiments with CLL, 15 samples 
were used to compare responses between soluble anti-IgM at 1 and 6 hours and 
10 further samples were used to compare responses to soluble and bead-bound 
anti-IgM. The statistical significance of differences between treated and control 
cells are shown for each condition (Student’s t-test). (C) Correlation between fold 
induction of XBP1 and CHOP RNAs in soluble/bead-bound anti-IgM treated CLL 
samples (1 and 6 hour data combined; linear regression and Spearman 
correlation shown). 
 
Figure 5. Regulation of BIP and PERK expression by anti-IgM 
 19 
CLL samples (n=15) were stimulated with soluble (sol) or bead-bound (bead) 
anti-IgM, or thapsigargin as a control (TG; 15 M) for up to 24 hours and 
expression of PERK, BIP and phosphorylated ERK1/2 was analyzed by 
immunoblotting. (A) Representative results from 2 CLL samples. Phosphorylated 
and non-phosphorylated forms of PERK are indicated by white and black 
triangles, respectively. (B) Quantitation of results. Expression values were 
normalized so that the average value in control cells at each time point was set to 
1.0 and graphs show mean values (±SD). The statistical significance of 
differences is shown. Vertical values show the P values for difference between 
that condition and control cells whereas horizontal values show P values for the 
differences between soluble and bead-bound anti-IgM-treated samples at each 
time point (paired Student’s t-test). (C) Correlation between fold induction of 
PERK and BIP in soluble/bead-bound anti-IgM-treated CLL samples (3, 6 and 24 
hours data combined; linear regression and Spearman correlation shown). 
 
Figure 6. UPR activation in CLL/SLL lymph nodes 
Immunohistochemical analysis of expression of (A,C,F) PERK, (B,D,G) XBP1 
and (E,H) Ki-67 in (A,B) multiple myeloma and (C-H) CLL/SLL lymph nodes. 
Original magnification of images are shown. Results are representative of a total 
of 11 biopsies analyzed. CLL PCs are circled and higher magnification images of 
the PC marked (*)  in C and D are shown in F and G. The insert in G shows the 
nuclear expression of XBP1 in the small CLL cells in contrast to the cytoplasmic 
expression in the large blasts in the proliferation centres. Arrows highlight large 
blasts in F and G. Images for C and F (PERK), and D and G (XBP1) are from 
samples 8 and 11, respectively. Inset shown in G is from sample 1. 
 
Figure 7. Effect of signaling inhibitors on anti-IgM-induced UPR activation 
Cells were pre-treated with DMSO, ibrutinib or tamatinib for 30 minutes before 
being stimulated with bead-bound anti-IgM or control antibodies. Expression of 
PERK, BIP, phosphorylated ERK1/2 and phosphorylated AKT was analyzed at 
24 hours. (A) Representative immunoblots. (B) Quantitation of results for all 
samples (n=6 for ibrutinib and tamatinib). Graphs show inhibition of PERK/BIP 
expression with anti-IgM/DMSO treated cells set to 100%. The statistical 
significance of differences between control and compound-treated control cells is 
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Supplementary Tables S1 and S2 


















































RNA analysis  
Total RNA was isolated using the RNeasy kit (QIAGEN, Crawley, UK) according to the 
manufacturer’s instructions and converted to cDNA using oligo(dT) primers and M-MLV 
reverse transcriptase (Promega, Southampton, UK). For analysis of XBP1S RNA we 
used the approach described previously (Bagratuni et al. 2010). For quantitative PCR (Q-
PCR), PCR reactions were performed using a 7500 Real Time PCR System and TaqMan 
Universal PCR Master Mix (Applied BioSystems, Warrington, UK) and the following 
TaqMan probes: Human B2M (beta-2-microglobulin) endogenous control (4333766T), 
XBP1 (Hs02856596_m1), CHOP (Hs99999172_m1). Relative RNA quantities were 
calculated with the equation RQ=2
-(∆∆CT)
 using B2M expression as an internal control and 
normalized so that the expression in normal B cells, or control CLL cells was set to 1.0. 
Published gene expression array (GEA) data (accession: GDS4176)
 
(Herishanu et al. 
2011) were analyzed using the NCBI Gene Expression Omnibus browser 
(http://www.ncbi.nlm.nih.gov/geo/). 
Protein analysis 
Immunoblotting was performed using the following antibodies: anti-phospho-ERK1/2 
(9101), anti-ERK1/2 (9102), anti-PERK (5683), anti-BIP (3183), anti-phospho-AKT 
(S473) (4060), anti-AKT (9272), anti-phospho-eIF2 (S51) (3597), anti-eIF2 (2103) (all 
from Cell Signaling Technology, Hitchin, UK), anti-XBP1 (619501; BioLegend, London, 
UK) and anti-β-actin (2066; Sigma-Aldrich, Poole, UK). Secondary horseradish 
peroxidase-conjugated antibodies were from GE Healthcare (Little Chalfont, UK). 
Densitometry analysis of immunoblot images was performed using Quantity One 
software (BioRad). In experiments with longer incubations (>6 hours), cells were treated 
with the caspase inhibitor zVADfmk (50 M, Calbiochem) to minimize secondary events 
due to apoptosis. 
Immunohistochemical analysis was performed using a tissue-microarray prepared from 
formalin fixed and paraffin embedded lymph node (LN) tissue sections from 11 cases of 
CLL/small lymphocytic lymphoma (SLL). Immunostaining was performed on sections 
after deparaffinisation and citrate buffer (pH 6.0) antigen retrieval with anti-XBP1 
(ab37152; Abcam), anti-PERK (5683; Cell Signaling Technology) or anti-Ki-67 (MIB1; 
Dako, Stockport, UK) primary antibodies at a 1:100 dilution. Diaminobenzidine was used 
for staining development and the sections were counterstained with Mayer’s 

















































For sIgM stimulation, CLL cells were cultured at 1x10
7
/ml and treated with 20 g/mL 
soluble goat F(ab')
2
 anti–human IgM (Southern Biotechnology, Cambridge, UK) or goat 
F(ab')
2
 anti–human IgM coated M-280 Dynabeads (Invitrogen, Paisley, UK). The 
preparation of anti-IgM-coated beads was as described.(Coelho et al. 2013) Cells were 
treated with antibody-coated beads at a ratio of 2 beads per cell. As controls, cells were 
treated with soluble or bead-bound, non-immune goat F(ab')
2
 (Southern Biotechnology). 
In experiments using chemical inhibitors, cells were pretreated with ibrutinib or tamatinib 
(both 10M; Selleckchem, Newmarket, UK) for 1 hour prior to stimulation with anti-IgM. 
Thapsigargin and brefeldin A were from Sigma-Aldrich. 
Statistics 
Statistical analyses were performed using GraphPad Prism 6 software (GraphPad, San 
Diego, CA, USA).  
Bagratuni T, Wu P, Gonzalez de Castro D, et al. XBP1s levels are implicated in the 
biology and outcome of myeloma mediating different clinical outcomes to thalidomide-
based treatments. Blood. 2010;116(2):250-253. 
Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes B-
cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic 


















































Binet stage at diagnosis. 
b
U, unmutated; M, mutated. 
c
% positive cells 
d




































































































Overview of UPR pathways. The UPR is controlled by three endoplasmic reticulum (ER)-
resident sensor proteins IRE1, PERK and ATF6. ER stress leads to dissociation of the ER 
chaperone BIP (GRP78) from these sensors leading to their activation. Full UPR activation 
is associated with ATF6 transit to the Golgi where it is proteolytically activated. The resultant 
50 kDa ATF6 fragment (p50 ATF6) is a nuclear transcription factor that induces expression 
of UPR-associated genes, including BIP, CHOP and XBP1, and components of the ERAD 
(endoplasmic reticulum-associated protein degradation) system. IRE1 undergoes 
autophosphorylation which activates its endoribonuclease activity resulting in a removal of  
26-base pair fragment from XBP1 RNA. The XBP1 splice variant is translated into XBP1S, a 
transcription factor which induces expression of chaperones and  ERAD proteins. The UPR 
is a highly flexible response system and variable activation of its downstream effector arms 
in different cell types or in response to stimuli of differing strength/duration, fine-tunes 
responses ranging from survival to apoptosis. Prolonged, high-level UPR responses are 
linked to cell death which is predominantly mediated by JNK1, downstream of IRE1, and, in 
some cell types, induction of CHOP. 
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Regulation of the UPR in thapsigargin-treated CLL cells 
CLL cells were treated with thapsigargin (TG; 15M) or left untreated as a control (Co). Cells 
were collected after 3, 6 or 24 hours. (A) Q-PCR analysis of CHOP and XBP1 RNA 
expression. (B) Immunoblot analysis of PERK, total eIF2, phosphorylated eIF2, BIP and 
-actin (loading control). Phosphorylated and non-phosphorylated forms of PERK are 
indicated by white and black triangles, respectively. For (A), CHOP/XBP1 RNA expression 
values were normalised to B2M expression and normalised expression values of control 
cells at 6 hours were set to 1.0. For (B), cells were incubated throughout the experiment in 
the presence of zVADfmk (50mM) to suppress apoptosis. Data shown were obtained using 























































XBP1S RNA expression in untreated and thapsigargin-treated CLL cells 
Analysis of full length and spliced XBP1 RNA in CLL cells using RT-PCR. BACT RNA 
expression is shown as a control. (A) Representative CLL sample treated with thapsigargin 
(TG; 15M). (B) Untreated CLL samples. Data shown are representative of results obtained 
with 30 different samples.  
Figure S3 
A B 



















































A B C 
D E F 
Correlations between CHOP and XBP1 RNA expression and prognostic 
features of CLL. 
Correlations between basal CHOP and XBP1 RNA expression and (A,B) IGHV 
mutation status, (C,D) CD38 expression and (E,F) ZAP70 expression in all samples. 

































































Effects of soluble or bead-bound anti-IgM on kinase activation 
CLL samples were stimulated with soluble (sol) or bead-bound anti-IgM (anti-IgM
bead
) 
or isotype control (IC) antibodies for up to 24 hours in the presence of zVADfmk. 




), phosphorylated AKT (S
473
) and β-
actin was analyzed by immunoblotting. Data shown are representative of results 

















































PERK and BIP expression in control and soluble anti-IgM-treated non-
responsive CLL samples. 
sIgM non-responsive CLL samples (n=4) were incubated with soluble anti-IgM 
for 3, 6 or 24 h and expression of PERK and BIP was analyzed by 
immunoblotting. Expression values were normalised so that the mean value in 
control cells at each time point was set to 1.0. Graphs show mean values 
(±SD). The statistical significance of the differences between control and anti-


















































Comparison of anti-IgM-induced PERK/BIP expression and ERK1/2 
phosphorylation in signal responsive samples.  
Parallel immunoblotting was used to quantify PERK, BIP and ERK1/2 
phosphorylation for 9 of the samples analyzed in Figure 5 of the main manuscript. 
Expression values were normalized to -actin. We then calculated the expression of 
each marker in bead-bound-anti-IgM treated cells relative to control cells at the 
same time point. Graphs include comparisons for data for all time points and show 
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PERK and BIP expression in control and anti-IgM-treated normal B cells. 
Normal B cells (anti-CD138-depleted) were incubated with soluble anti-IgM or 
isotype control antibody for 6 or 24 h and expression of PERK, BIP and -actin 
(loading control) was analyzed by immunoblotting. Results are representative of 
































A model linking differential antigen signaling via sIgM to modulation of 
the UPR. 
Antigen signaling results in two predominant signaling responses in CLL; 
anergy linked to a good prognosis and “positive” growth-promoting signaling 
linked to more aggressive behavior. BCR-induced UPR activation appears to be 
linked to positive signaling since basal UPR expression is highest in the subset 
of samples which retain sIgM signaling responsiveness and is further elevated 
following treatment with anti-IgM in vitro in signal responsive samples. 
